丙型肝炎患者获得持续病毒学应答后代偿性肝硬化再代偿的预后意义
多中心观察性研究纳入916例HCV相关肝硬化患者,SVR后随访至少12个月。基线失代偿者中63.4%在12个月时实现再代偿;再代偿者死亡率低于失代偿者但仍高于代偿者,而HCC风险在再代偿队列中未下降。
要点
- 基线失代偿的216例患者中,63.4%(137/216)在SVR后12个月实现再代偿。
- 代偿组死亡率4.2%低于再代偿组36.5%和失代偿组50%(p=0.0001)。
- 代偿组HCC发生率4.4%低于再代偿组14.4%和失代偿组12.1%(p=0.0001)。
核心结论
- 三分之二的失代偿期肝硬化患者在SVR后12个月实现再代偿。
- 再代偿患者生存优于失代偿患者,但仍差于代偿患者。
- 再代偿队列的HCC风险未降低。
研究设计与样本
- 多中心观察性研究,纳入916例HCV相关肝硬化且SVR后随访至少12个月的患者。
- 患者分为代偿、失代偿和再代偿三个互斥组,随访至肝移植、死亡或末次随访。
主要发现
- 研究期间(4.5±2.5年),12%(110/916)发生失代偿事件,7.7%(71/916)诊断HCC,14.9%(137/916)死亡。
- 基线失代偿者占23%(216/916),其中63.4%(137/216)在12个月时实现再代偿。
- Child-Pugh评分(OR 0.69;95%CI 0.53-0.89;p=0.005)和既往失代偿事件次数与再代偿相关。
- 死亡率:代偿组4.2%(28/663)低于再代偿组36.5%(50/137)和失代偿组50%(30/60)(p=0.0001)。
- HCC发生率:代偿组4.4%(29/662)低于再代偿组14.4%(19/132)和失代偿组12.1%(7/58)(p=0.0001)。
关键数值与推荐
- 再代偿与死亡率相关(CSHR 0.30;95%CI 0.19-0.49;p=0.0001),代偿状态亦相关(CSHR 0.09;95%CI 0.05-0.16;p=0.0001)。
- 年龄(CSHR 1.03;95%CI 1.01-1.05;p=0.0009)、白蛋白(CSHR 0.67;95%CI 0.45-0.98;p=0.038)、INR(CSHR 1.88;95%CI 1.14-3.10;p=0.014)和胆红素(CSHR 1.28;95%CI 1.08-1.50;p=0.003)与死亡率相关。
临床怎么用
- 再代偿患者生存仍低于代偿患者,HCC风险未降低,应维持HCC筛查。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGOUND & AIMS: The Baveno VII consensus introduced the term "recompensated cirrhosis," though few studies have examined its clinical relevance. We analyzed the rate and predictors of recompensation after sustained virological response (SVR) in patients with HCV and evaluated its impact on mortality and hepatocellular carcinoma (HCC) compared to compensated and decompensated cirrhosis. METHODS: We performed a multicenter observational study enrolling 916 patients with HCV-related cirrhosis with a minimum follow-up period of 12 months after SVR. Patients were categorized into three mutually exclusive groups: compensated, decompensated, and recompensated. Patients were followed until the occurrence of liver transplantation, death, or the last follow-up date, whichever came first. RESULTS: During the study (4.5 ± 2.5 years), 12% (110/916) experienced a decompensating event, 7.7% (71/916) were diagnosed with HCC, and 14.9% (137/916) died. Among the 23% (216/916) of patients who were decompensated at baseline, 63.4% (137/216) achieved recompensation at 12 months. Child-Pugh score (odds ratio 0.69; 95% CI 0.53-0.89; p = 0.005) and the number of past decompensating events were associated with recompensation. The compensated cohort exhibited a lower mortality rate (4.2% [28/663]) than recompensated (36.5% [50/137]) and decompensated (50% [30/60]) patients (p = 0.0001). Along with age (cause-specific hazard ratio [CSHR] 1.03; 95% CI 1.01-1.05; p = 0.0009), albumin (CSHR 0.67; 95% CI 0.45-0.98; p = 0.038), international normalized ratio (CSHR 1.88; 95% CI 1.14-3.10; p = 0.014), and bilirubin levels (CSHR 1.28; 95% CI 1.08-1.50; p = 0.003), recompensated (CSHR 0.30; 95% CI 0.19-0.49; p = 0.0001) and compensated (CSHR 0.09; 95% CI 0.05-0.16; p = 0.0001) states were associated with mortality. By contrast, HCC occurrence was significantly lower in compensated (4.4% [29/662]) than recompensated (14.4% [19/132]) and decompensated (12.1% [7/58]) patients (p = 0.0001). CONCLUSIONS: Two-thirds of patients with decompensated cirrhosis achieved recompensation 12 months after SVR. Survival was better in recompensated patients than in decompensated patients, but still worse than in compensated patients. However, HCC risk remained unchanged in the recompensated cohort. IMPACT AND IMPLICATIONS: The Baveno VII consensus introduced the term "recompensated cirrhosis," though few studies have examined its clinical relevance in hepatitis C. Two out of every three patients with decompensated cirrhosis achieved recompensation 12 months after sustained virological response. Recompensated patients had a better survival rate than those who did not experience clinical resolution of decompensation, although their survival remained lower than that of compensated patients. Hepatocellular screening should be maintained, as its risk did not decrease in the recompensated cohort.
引用
- Sánchez-Torrijos Y, Fernández-Álvarez P, Rosales JM, et al. Prognostic implications of recompensation of decompensated cirrhosis after SVR in patients with hepatitis C. J Hepatol. 2025. PMID: 40056934. doi:10.1016/j.jhep.2025.02.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。